Abstract:Xiaobo Li, 1, 2 Chen Yu, 1 Xuewei Liu, 3 Yejia Chen, 1 Yutian Wang, 1 Hongbin Liang, 1 ShiFeng Qiu, 1 Li Lei, 1 Jiancheng Xiu 1 1 Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China; 2 Department of Cardiology, Xiangdong Hospital, Hunan Normal University, Liling, Hunan, People's Republic of China; 3 The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Southern Medical University, Dongguan, Guangdong, People's Republic of China Correspondence: Jiancheng Xiu, Tel +8613903064940, Email Objective: To evaluate the prognostic value of the systemic immune-inflammatory index (SII) for predicting in-hospital major adverse cardiovascular events (MACEs) in patients with acute myocardial infarction (AMI) and establish a relevant nomogram. Methods: This study included 954 AMI patients. We examined three inflammatory factors (SII, platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR)) to see which one predicts in-hospital MACEs better. The predictors were subsequently screened using bidirectional stepwise regression method, and a MACE nomogram was constructed via logistic regression analysis. The predictive value of the model was evaluated using the area under the curve (AUC), sensitivity and specificity. In addition, the clinical utility of the nomogram was evaluated using decision curve analysis. We also compared the nomogram with the Global Registry of Acute Coronary Events (GRACE) scoring system. Results: 334 (35.0%) patients had MACEs. The SII (AUC =0.684) had a greater predictive value for in-hospital MACEs in AMI patients than the PLR (AUC =0.597, P< 0.001) or NLR (AUC=0.654, P=0.01). The area under the curve (AUC) of the SII-based multivariable model for predicting MACEs, which was based on the SII, Killip classification, left ventricular ejection fraction, age, urea nitrogen (BUN) concentration and electrocardiogram-based diagnosis, was 0.862 (95% CI: 0.833– 0.891). Decision curve and calibration curve analysis revealed that SII-based multivariable model demonstrated a good fit and calibration and provided positive net benefits than the model without SII. The predictive value of the SII-based multivariable model was greater than that of the GRACE scoring system (P< 0.001). Conclusion: SII is a promising, reliable biomarker for identifying AMI patients at high risk of in-hospital MACEs, and SII-based multivariable model may serve as a quick and easy tool to identify these patients. Keywords: systemic immune-inflammatory index, major adverse cardiovascular events, inflammation, acute myocardial infarction Acute myocardial infarction (AMI) is a major cause of mortality worldwide and accounts for one-third of deaths in developed countries. 1 AMI results from acute and persistent ischemia and hypoxia of the coronary arteries caused by rupture or erosion of unstable atherosclerotic plaques, leading to myocardial necrosis. 2 Although the application of interventional therapy and improvements in drug treatments have reduced the mortality of AMI patients, the residual risk of cardiovascular events in patients remains high. 3,4 The number of hospitalized AMI patients has generally increased in the past decade, while the hospitalization mortality rate has not decreased. 5–7 Early identification of high-risk patients who may develop major adverse cardiac events (MACEs) after AMI is crucial for enhancing patient prognosis. Traditional risk scoring systems, such as the Global Registry of Acute Coronary Events (GRACE), have been used to predict in-hospital death, recurrence of myocardial infarction (MI) and other MACEs in AMI patients. 8 However, the predictive effectiveness of these systems, which were developed in clinical trials more than 20 years ago, may be limited due to their lack of consideration of currently widely used therapies such as drug-eluting stents (DESs) and new-generation antiplatelet therapies. 9 Discovering new predictors and developing new reliable risk scoring systems for AMI patients are necessary. Time is life, and time is the myocardium. For AMI patients, emergency treatment is often needed, especially for patients at high risk of in-hospital MACEs. However, there are few indicators that can be used to predict in-hospital MACEs in patients with AMI due to the urgency of timely diagnosis. Cardiovascular diseases are characterized by a high inflammatory burden, stable coronary artery disease and acute coronary syndrome can both lead to an increase in inflammatory markers in the blood. 10–12</ -Abstract Truncated-

Admission Macrophage Migration Inhibitory Factor Predicts Long-Term Prognosis in Patients with ST-elevation Myocardial Infarction

Macrophage migration inhibitory factor for the early prediction of infarct size.

Changes of Plasma Macrophage Migration Inhibitory Factor Level in Patients with Acute Myocardial Infarction and Its Clinical Significance

Long-term prognostic value of macrophage migration inhibitory factor in ST-segment elevation myocardial infarction patients with metabolic syndrome after percutaneous coronary intervention

Prognostic Significance and Dynamic Change of Plasma Macrophage Migration Inhibitory Factor in Patients with Acute ST-elevation Myocardial Infarction.

Correlation Between Plasma Macrophage Migration Inhibitory Factor Levels and Long-Term Prognosis in Patients with Acute Myocardial Infarction Complicated with Diabetes

Serum level of macrophage migration inhibitory factor predicts severity and prognosis in patients with ischemic stroke

Plasma Macrophage Migration Inhibitor Factor is Elevated in Response to Myocardial Ischemia

Prognostic Value of the Percentage of Neutrophils on Admission in Patients with ST-elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Association of Serum Macrophage Migration Inhibitory Factor with 3-Month Poor Outcome and Malignant Cerebral Edema in Patients with Large Hemispheric Infarction

Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Non-ST-Segment Elevation Myocardial Infarction Patients

Predictors of 1-year follow-up period MACE in patients with NSTEMI

The Admission (Neutrophil+Monocyte)/Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Patients With Acute Myocardial Infarction

The prediction value of platelet-derived growth factor for major adverse cardiovascular events in patients with acute non-ST-segment elevation myocardial infarction

[Predictive value of neutrophil to lymphocyte ratio on long-term outcomes of acute myocardial infarction patients with multivessel disease].

A Prediction Model Based on Systemic Immune-Inflammatory Index Combined with Other Predictors for Major Adverse Cardiovascular Events in Acute Myocardial Infarction Patients

Acute Response in the Noninfarcted Myocardium Predicts Long-Term Major Adverse Cardiac Events After STEMI

Immune-inflammatory biomarkers for the occurrence of MACE in patients with myocardial infarction with non-obstructive coronary arteries

Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention.

Prognostic Value of Circulating MG53 Levels in Acute Myocardial Infarction

Macrophage Migration Inhibitory Factor Gene Polymorphism in Acute Coronary Syndrome